$RDVT

MacLachlan Daniel sold $689K of RDVT

MacLachlan Daniel (Chief Financial Officer) sold 12,000 shares of Red Violet, Inc. (RDVT) at an average of $57.43 ($57.24–$57.62, $0.69M total) across 2 trades on 2026-06-01.

Original reporting
SEC EDGAR · MacLachlan Daniel
Published Jun 1, 2026, 11:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RDVT
Bearish
medium confidence
Mentioned
$RDVT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDVTBearishLow
01

Why it matters

The CFO's sale may be interpreted as a negative signal, prompting short sellers.

02

Market read

A CFO insider sale of $689k could cause short-term price pressure on RDVT.

03

What to watch

Potential upcoming corporate actions or personal financial needs not disclosed.

Relevance 5/10Novelty 3/10Timing: same-day

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$RDVTBearishMedium confidence
Context

CFO Daniel MacLachlan sold 12,000 shares for $689,160 in a Form 4 filing.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

A CFO selling a sizable stake, even if under $1M, often triggers short-term sell pressure.

Market effects

Minimal impact on the broader sector; only relevant to RDVT investors.

No regional effect beyond the company's trading venue.

Negligible on a global scale.

Counterpoint

The sale could be a routine liquidity move, not a lack of confidence.

Key entities

  • Red Violet, Inc.

    Issuer of the shares sold.

  • Daniel MacLachlan

    Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RDVTMed

Red Violet (RDVT) Turns Record Growth Into Real Profit Gains

Red Violet (RDVT) reported Q2 2026 revenue of $26.7M, up 23%, and net income of $5M, nearly doubling. Gross margin increased to 76%, and adjusted EBITDA rose 48% to $11.2M. The company added 447 new customers and 25,493 new users for its FOREWARN product. Red Violet raised $109M in an August offering, bringing cash to $160M with no debt. CEO Derek Dubner highlighted a strong pipeline of initiatives. The company repurchased 74,500 shares at an average price of $41.87.

$RDVTMed

Red Violet, Inc. (RDVT): Record Revenue of $26.7 Million, an Increase of 23%; Record Cash Flow from Operations of $10.6 Million

Red Violet, Inc. (RDVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 red violet Reports Second Quarter 2026 Financial Results Record Revenue of $26.7 Million, an Increase of 23%; Record Cash Flow from Operations of $10.6 Million BOCA RATON, Fla. – August 10, 2026 – Red Violet, Inc. (NASDAQ: RDVT), a leading identity intelligence and a

$RDVTMedAI 8/10

red violet Announces Closing of $115 Million Underwritten Public Offering of Common Stock, Including Full Exercise of Underwriters' Option

Red Violet, Inc. (NASDAQ: RDVT) said it closed an underwritten public offering of 1,916,667 shares of common stock, including 250,000 shares from full exercise of the underwriters’ option. The company estimates net proceeds of about $108.6 million. Proceeds will be used for working capital, general corporate purposes, and potential strategic acquisitions.

$RDVTMedAI 8/10

red violet Announces Pricing of $100 Million Underwritten Public Offering of Common Stock

Red Violet, Inc. (NASDAQ: RDVT) priced an underwritten public offering of 1,666,667 shares of common stock at $60.00 per share, raising expected gross proceeds of $100 million before underwriting fees and expenses. The offering is expected to close Aug. 7, 2026, with a 30-day option for up to 250,000 additional shares. Net proceeds will fund working capital and corporate purposes.